It is with interest that we read the announcement from the Department of Health Services, Office of Inspector General (OIG) with respect to review of Medicare part B Urine drug testing (UDT) services for patients with substance abuse disorder. It was reported that, in 2018, there was a 30% improper payment rate for UDT and 71.7% overpayment rate for definitive drug testing for 22 or more drug classes. [1] The OIG is currently reviewing UDT services regarding allowable services for substance use disorder related diagnoses.

中文翻译：

---

需要基于证据的尿液药物检测方案来改善结果

我们感兴趣地阅读了卫生服务部监察长办公室 (OIG) 关于审查医疗保险 B 部分尿液药物检测 (UDT) 服务为药物滥用障碍患者提供的公告。据报道，2018年，22个或更多药物类别的UDT不当支付率为30%，最终药物检测的多付率为71.7%。[1] OIG 目前正在审查有关物质使用障碍相关诊断的允许服务的 UDT 服务。